Pacemaker News and Research

RSS

HeartWare International acquires CircuLite

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it has acquired CircuLite, Inc. – developer of the SYNERGY Circulatory Support System, designed to treat less sick, ambulatory, chronic heart failure patients who are not yet inotrope-dependent.

1 Dec 2013

Heart failure patients may benefit from advanced treatment by heart specialists

New research from Karolinska Institutet in Sweden shows that patients with heart failure have high mortality and often are undertreated. According to a study, published in the scientific periodical JACC, many more of these patients would benefit from advanced treatment by heart specialists - something that could be decided by a simple evaluation of five common risk factors for early death due to heart failure.

4 Nov 2013

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.

31 Oct 2013

Multidisciplinary team tests innovative heart failure therapy in global clinical trials

A multidisciplinary team of experts in heart failure, cardiac arrhythmia, and neurosurgery at The Mount Sinai Hospital are now testing nerve stimulation in the neck as a novel therapy for heart failure patients to potentially help relieve their debilitating symptoms of fatigue, shortness of breath, and heart arrhythmias, while reducing their hospitalizations.

30 Oct 2013

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia.

18 Oct 2013

Respicardia awarded U.S. Healthcare Product of the Year for remede System

Respicardia®, Inc., a developer of implantable therapies to improve respiratory and cardiovascular health, announced that it has been awarded the U.S. Healthcare Product of the Year by Acquisition International for the remede System, the first and only implantable device for the treatment of central sleep apnea.

16 Oct 2013

CU researchers explore why maximum heart rate decreases with age

Researchers at the University of Colorado have new insight into the age-old question of why maximum heart rate decreases with age. This decrease in maxHR not only limits the performance of aging athletes but it is also a leading cause for nursing home admittance for otherwise-healthy elderly individuals who no longer have the physical capacity required for independent living.

16 Oct 2013

St. Jude Medical completes Nanostim acquisition; leadless pacemaker receives CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced the completion of its acquisition of Nanostim, Inc., a privately-owned developer of miniaturized, leadless pacemakers.

15 Oct 2013

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

ARIAD Pharmaceuticals, Inc. today announced results of its review of updated clinical data from the pivotal PACE trial of Iclusig® (ponatinib) and actions that it is taking following consultations with the U.S. Food and Drug Administration (FDA).

9 Oct 2013

Digital security: an interview with Jon Edgcombe, leader of the software technologies group at Cambridge Consultants

Digital security is a key requirement in our product designs, especially in markets such as healthcare where the design is complete long before final regulatory approval. From a commercial point of view, ignoring data privacy, device authentication, and anti-counterfeit at design stage is no longer a tenable position for a connected product that produces sensitive patient data – even if it is nominally pseudonomised.

2 Oct 2013

Ilesto ICD/CRT-D devices from BIOTRONIK approved by FDA

BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced it has received approval from the Food and Drug Administration (FDA) for its Ilesto family of implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillators (ICD/CRT-D devices). BIOTRONIK follows this milestone with the launch of its next generation unique technology platform Ilesto DX.

1 Oct 2013

Rice University researchers come up with touch-to-access security for implanted devices

Pacemakers, insulin pumps, defibrillators and other implantable medical devices often have wireless capabilities that allow emergency workers to monitor patients. But these devices have a potential downside: They can be hacked.

24 Sep 2013

Respicardia reports results from remede System Pilot Study for central sleep apnea treatment

Respicardia, a developer of implantable therapies to improve respiratory and cardiovascular health, announced results from the remede System Pilot Study during the Heart Failure Society of America Late Breaking Scientific Session in Orlando. Dr. William T. Abraham of The Ohio State University Wexner Medical Center in Columbus presented the results for the first and only implantable device for respiratory rhythm management to treat central sleep apnea.

24 Sep 2013

Implantation rate of CIEDs continues to rise in most European countries

Infections cause a lower proportion of lead extractions than expected, according to preliminary results from the ELECTRa Registry presented at ESC Congress 2013 today by Dr Maria Grazia Bongiorni from Italy.

3 Sep 2013

Pacemakers implanted for slow heart rhythm restore life expectancy to normal levels

Pacemakers implanted for slow heart rhythm restore life expectancy to normal levels, reveals research presented at ESC Congress 2013 today by Dr Erik O. Udo from the Netherlands. The findings provide a new reference point for the prognosis of modern pacemaker patients.

2 Sep 2013

Johns Hopkins researchers use low-energy light to solve serious heart problems

When a beating heart slips into an irregular, life-threatening rhythm, the treatment is well known: deliver a burst of electric current from a pacemaker or defibrillator. But because the electricity itself can cause pain, tissue damage and other serious side-effects, a Johns Hopkins-led research team wants to replace these jolts with a kinder, gentler remedy: light.

29 Aug 2013

Pacemaker News and Research

HeartWare International acquires CircuLite

Heart failure patients may benefit from advanced treatment by heart specialists

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

Multidisciplinary team tests innovative heart failure therapy in global clinical trials

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

Respicardia awarded U.S. Healthcare Product of the Year for remede System

CU researchers explore why maximum heart rate decreases with age

St. Jude Medical completes Nanostim acquisition; leadless pacemaker receives CE Mark approval

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

Digital security: an interview with Jon Edgcombe, leader of the software technologies group at Cambridge Consultants

Ilesto ICD/CRT-D devices from BIOTRONIK approved by FDA

Rice University researchers come up with touch-to-access security for implanted devices

Respicardia reports results from remede System Pilot Study for central sleep apnea treatment

Implantation rate of CIEDs continues to rise in most European countries

Pacemakers implanted for slow heart rhythm restore life expectancy to normal levels

Johns Hopkins researchers use low-energy light to solve serious heart problems

Respicardia reports successful implant of remede System for CSA patients

Compounds found in red wine and green tea can be used as antibacterial coating

Researchers uncover role of IKACh in pacemaker activity and heart rate regulation

Breaking habits is easy, reveal MIT researchers

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News